The
global Microbiology Testing/Clinical Microbiology Market is expected to reach USD 4.95 billion by
2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast
period. The technological advancements in the disease diagnostics, rising
incidence of infectious diseases and growing outbreak of epidemics, and
increased funding and public-private investments in the field of disease
diagnosis are the key factors driving the growth of the clinical microbiology
market during the forecast period.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=219135367
Strategic
analysis of the market developments between 2014 and 2018 revealed that growth
strategies such as product launches and enhancements; acquisitions; agreements,
partnerships, collaboration; and expansions were adopted by the market players
to strengthen their product portfolios and maintain a competitive position in
the clinical microbiology market. Among these business strategies, product launches
& enhancements and partnerships & collaborations were the two most widely
adopted growth strategies.
bioMérieux S.A. (France) held the
leading position in the global clinical microbiology market in 2017. The
company has a robust product portfolio and a strong geographical presence in
more than 150 countries across the world. To
maintain its leadership position in the market, the company has been
focusing on R&D activities and product launches. In 2017, the company
invested ~13% of its revenue in R&D activities, with the aim to improve
product quality,
accuracy, and reduce the overall throughput time required for
a test. The company launched several products in the clinical testing space in
the past four years, such as VITEK MS, FilmArray 2.0, VIDAS C. difficile GDH
assay kit, GENE-UP diagnostic solution, ChromID Salmonella ELITE, and FilmArray
Ebola test, among others. It also aims to increase its geographical presence
and strengthen its product portfolio through growth strategies such as partnerships, collaborations, and expansions. In
line with this, in 2017, the company established a new R&D center in France,
which is a new multidisciplinary R&D center for infectious disease
diagnostics. Further, in 2015, the company entered into a distribution
agreement with COPAN (Italy), which helped the company to expand its product
portfolio.
Danaher Corporation (US) held the second
position in the global clinical microbiology market in 2017. The company
operates in the clinical microbiology testing market through its wholly owned
subsidiaries— Beckman Coulter and Cepheid. Danaher is focusing on strengthening
its position in the global clinical microbiology market mainly by adopting
strategies such as acquisitions and new product launches. The acquisition of
Beckman Coulter Inc. (a major player in the US life sciences and diagnostics
market) in June 2011 helped the company strengthen its product portfolio and
increase its share in the clinical microbiology testing market. The acquisition
of Cepheid in November 2016 further helped to enhance the company’s position,
expand its molecular diagnostic products portfolio, and increase its market
share in the clinical microbiology testing market. The company also acquired
Siemens Healthcare’s clinical microbiology business (July 2014) and Xitogen
Technologies Inc. (April 2014) to strengthen its
product offerings and geographic presence. The
company launched several innovative products, such as DxM 6100 Autoplak Advanced
System, Xpert Xpress Flu Test Kit, DxONE Clinical Information Management Tools,
VERIS Human CMV Assay, and UniCel DxH Connected Workcell Solution, among others.
These products have helped the company remain competitive in the microbiology
testing market.
To Know More @
No comments:
Post a Comment